Beta-blockers may improve survival in epithelial ovarian cancer

the ONA take:

Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer, according to a new study published today in the journal Cancer.

For the study, researchers from The University of Texas MD Anderson Cancer Center in Houston, TX, retrospectively analyzed the medical records of 1,425 women with epithelial ovarian cancer treated between 2000 and 2010 in order to evaluate the impact of beta-blocker use during chemotherapy on overall survival.

Among 269 patients who received beta-blocker therapy, about 72% received beta-1 adrenergic receptor selective agents like atenolol, metoprolol, and bisoprolol, while the rest received nonselective beta-blockers, such as propranolol, carvedilol, and labetalol.

Results showed that median overall survival for beta-blocker and non-beta-blocker users was 47.8 months and 42 months, respectively.

Researchers found that patients receiving selective beta-1 blockers had a median overall survival of 94.9 months vs 38 months for those receiving non-selective beta antagonists.

The researchers note, however, that further studies are required before beta-blockers are recommended as adjuvant therapy in patients with ovarian cancer undergoing surgery.

Beta-blockers may improve survival in epithelial ovarian cancer
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs